Johnson & Johnson Innovation Spotlight 2021
In a year of change, Johnson & Johnson Innovation supported the European innovation ecosystem to adapt and pivot to continue addressing high unmet needs across all areas of health.
LONDON, UK
The Johnson & Johnson Innovation team based in London, UK provides a gateway into the Johnson & Johnson Family of Companies for innovators across Europe and beyond to generate potentially transformational healthcare solutions through value-creating collaborations.
EMEA FOOTPRINT
Collaborating with a Digital Health Spinout
BARCELONA, SPAIN
Koa Health is collaborating with Janssen Research & Development to research the use of digital cognitive behavioural therapy in combination with a pharmacological treatment, for treatment-resistant major depressive disorder patients.
JLABS
BEERSE, BELGIUM
Johnson & Johnson Innovation - JLABS (JLABS) provides life sciences innovators with a strong global expert community, mentorship, education, investment opportunities, physical infrastructure, operations and much more to help them accelerate their business.
Incubating an Early Stage Innovation Company
GRENOBLE, FRANCE
Remedee Labs is a current resident of JLABS @ BE, who aims to use their patented technology platform to stimulate endogenous neurotransmitters, specifically endorphins.
They focus on chronic pain management and neurology. The company uses a therapy based on millimetre waves to non-invasively stimulate nerve endings on highly innervated areas of the body.
Collaborating within a Consortium
LONDON, UK
Janssen Research & Development is collaborating with UK Biobank and a consortium of nine biopharmaceutical companies to measure circulating concentrations of 1,500 plasma proteins in approximately 53,000 UK Biobank participants.
It will be one of the world’s largest studies of blood protein proteomics and aims to significantly enable a better understanding of disease processes associated with gene expression to support innovative drug discovery.
JJDC
Johnson & Johnson Innovation - JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson. Our experienced investors work to identify transformational ideas in the external ecosystem, and through investment and advice, helps them to mature into solutions for patients.
STRATEGIC THERAPEUTIC AREAS
Collaborating with Academics and Research Institutions
Project iDx-LUNG
SOUTHAMPTON, UK
The Lung Cancer Initiative at Johnson & Johnson joined a collaboration with the UK University of Southampton and University of Leeds. The project aims to test the best way of detecting cancers when they are at a stage when they can still be cured, to increase survival rates amongst lung cancer patients.
Project iDx-LUNG will look to improve the efficiency of testing in people who are at high risk of cancer. The study encompasses 15,000 people who attend NHS England lung health checks at mobile CT scanners in Hampshire and Yorkshire. Blood samples and nasal swabs will be collected, which will be analysed for changes that could indicate early cancer development.
Cartography Collaboration
OXFORD, UK
Janssen Research & Development and the University of Oxford entered a collaboration to advance our understanding of immune-mediated inflammatory disorders, so that new therapies can be developed where existing options are limited.
The Cartography Collaboration will see the development of a cellular map of genes and proteins across a range of immune-mediated inflammatory disorders. It aims to support the characterisation of pharmacologically relevant therapeutic targets for precision medicine.
The study will focus on inflammatory disease indications of the intestine, the joints, and the skin.
Understanding Human Genetic Signatures
OXFORD, UK
Janssen Research & Development and The University of Oxford’s Big Data Institute began a strategic collaboration, to leverage data science capabilities to unlock disease insights and deliver better patient outcomes.
Through the collaboration, the Big Data Institute aims to appoint Fellows to work alongside Janssen scientists on projects to accelerate the translation of human genetic data to disease states by identifying linkages to causal events in disease processes.
Initially, the focus will be on areas of mutual interest and deep knowledge for both parties in inflammatory disorders, novel neuroscience linkages and basic methodologies in population datasets.
Investing in Medical Devices Technology Companies
STRASBOURG, FRANCE
Ethicon and Visible Patient have partnered to bring surgeons a clear roadmap for surgery.
Visible Patient Planning is a medical device software that is CE marked and FDA cleared. It creates a highly detailed, virtual 3D model using patient’s CT or MRI scans to provide a clearer road map for surgery. Visible Patient leverages algorithms and medical expert analysis to generate an interactive 3D model for organs such as the lungs, colon, kidneys and liver.
Ethicon is pleased to be the global marketing and sales partner in the collaboration, offering surgeons a tool that enables preoperative planning - when and where they choose - and the flexibility to reference their plan intra operatively.
Visible Patient helps surgeons see and meet clinical needs of surgical procedures with its Anatomical Atlas, 3D model, and Clip Applying Tool* - enabling more precise pre-operative planning.
* Currently available for Lung, Liver, and Kidney.
HOW WE HAVE COLLABORATED IN EMEA SINCE 2013
ORGANISATION COLLABORATIONS
COUNTRY COLLABORATIONS
COLLABORATION STRUCTURES
